US-based biopharmaceutical company Trevi Therapeutics has finished enrolling subjects in a Phase IIb trial of investigational ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Trevi Therapeutics (TRVI)has completed enrollment in its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Stifel analyst Annabel Samimy raised the firm’s price target on Trevi Therapeutics (TRVI) to $12 from $8 and keeps a Buy rating on the shares ...

Stifel maintained a Buy rating on the shares. Why Stifel Is More Bullish on TRVI With Trevi poised to soon announce data from a trial of its Haduvio drug as a treatment for refractory chronic cough ...

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions.

Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER ...

About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release ...

"The completion of enrollment in the Phase 2b CORAL trial is a significant milestone in the development of Haduvio for patients with idiopathic pulmonary fibrosis suffering from chronic cough ...

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in ...